Abbott announced that a new generation of an everolimus-eluting coronary stent system for treatment of patients with complex blockages associated with CAD has received approval from the FDA.
Compared with prior generations, the coronary stent system (Xience Sierra, Abbott) has a thinner profile, longer lengths, increased flexibility and small diameters to access multiple or totally blocked vessels in patients, according to a press release from the company.
This activity is supported by educational funding provided by Amarin Pharma Inc., Amgen, and Quest Diagnostics.
Heart Rhythm Society Scientific Sessions
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2018 Healio All Rights Reserved.